*Onset as early as day 1, typically within 2 days. Based on pooled
patient diary data from SAKURA 1 and SAKURA 2. 74% of patients in
clinical studies had improvement at week 4 per both physician's and
patient's assessments. At least 50% of patients in SAKURA 1 and
SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and
23.9 weeks (6 months) or longer, respectively, per both
investigator’s and patient’s assessments. 64% of patients achieved
an improvement in the appearance of skin texture at week 2 from a
post hoc analysis of a Phase 2 clinical study with 60 patients.
Peptide Powered
Discover our award-winning formulation and optimize patient results
with the only neuromodulator formulated with Peptide Exchange
Technology™ (PXT).4-8
*Onset as early as day 1, typically within 2 days. Based on pooled
patient diary data from SAKURA 1 and SAKURA 2. 74% of patients in
clinical studies had improvement at week 4 per both physician's and
patient's assessments. At least 50% of patients in SAKURA 1 and
SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and
23.9 weeks (6 months) or longer, respectively, per both
investigator’s and patient’s assessments. 64% of patients achieved
an improvement in the appearance of skin texture at week 2 from a
post hoc analysis of a Phase 2 clinical study with 60 patients.
DAXXIFY® is what your patients are looking for
Most patients get fewer than 2 neuromodulator treatments a year.9 DAXXIFY® provides sustained glabellar line improvement with the convenience
of as few as 2 treatments per year for busy patients.10*
*At least 50% of patients in SAKURA 1 and SAKURA 2 had none or mild
frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or
longer, respectively, per both investigator’s and patient’s
assessments.10
